FIELD: urology.
SUBSTANCE: treatment consists in administration of alpha-1-adrenoblocker. Therapy is continued within 4-8 weeks in effective dose. Method leads to aggravation of symptoms of disease during the treatment followed by stopping manifestations of disease after cessation of giving preparation due to elimination of disbalance in functioning of current-coordinated detrusor-cervix-urethra system.
EFFECT: expanded possibilities in treatment of stress-caused urological diseases.
7 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PREPARATION FOR TREATING SPINAL MARROW ISCHEMIA AND ASSOCIATED ISCHEMIA OF OTHER ORGANS | 2008 |
|
RU2375062C2 |
| METHOD OF URINARY INCONTINENCE TREATMENT OF MEN WITH SLING IMPLANTATION | 2007 |
|
RU2333724C2 |
| METHOD FOR CONSERVATIVE TREATMENT OF URINARY DISORDERS | 2021 |
|
RU2781885C1 |
| METHOD FOR DETECTING THE TYPE FOR TREATING PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA | 2001 |
|
RU2205001C2 |
| METHOD FOR DIAGNOSING URINATION DISORDERS | 2005 |
|
RU2303397C1 |
| METHOD OF MINIMALLY INVASIVE TREATMENT OF STRESS URINARY INCONTINENCE IN WOMEN | 2018 |
|
RU2748118C1 |
| METHOD OF TREATING ENURESIS AFTER RADICAL PROSTATECTOMY | 2013 |
|
RU2526400C1 |
| COMPOSITION FOR TREATMENT AND/OR PREVENTION OF LOWER URINARY TRACT SYMPTOMS | 2020 |
|
RU2808426C2 |
| METHOD FOR SURGICAL MANAGEMENT OF STRESS URINARY INCONTINENCE IN WOMEN | 2023 |
|
RU2822012C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING URINARY DISTURBANCES | 2012 |
|
RU2497504C1 |
